Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥180.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥6.1bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥6.2bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥5.0bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.2bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥137.3bnat 2024-09-30Cons.Assets
Total assets¥117.8bnat 2024-03-31Cons.Assets
Total assets¥107.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥79.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥64.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥58.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥52.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥27.3bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥477m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥265m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥8.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥32.432024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥131.112023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio39.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio44.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥64m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥7.4bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥622m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥928m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.7bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.5bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥124.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥686m
—segment totalsegment profit2024-04-01 → 2024-09-30¥7.9bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥173m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥801m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥142m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥237m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Income before income taxesPrior1YTDDuration3612000000JPY
Income before income taxesCurrentYTDDuration5001000000JPY
Income taxesPrior1YTDDuration1731000000JPY
Income taxesCurrentYTDDuration2667000000JPY
Profit lossPrior1YTDDuration1880000000JPY
Profit lossCurrentYTDDuration2334000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration-7000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration1122000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1888000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1211000000JPY
Profit lossPrior1YTDDuration1880000000JPY
Profit lossCurrentYTDDuration2334000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration13000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration10000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration490000000JPY
Other comprehensive incomePrior1YTDDuration13000000JPY
Other comprehensive incomeCurrentYTDDuration501000000JPY
Comprehensive incomePrior1YTDDuration1894000000JPY
Comprehensive incomeCurrentYTDDuration2836000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration1901000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration1473000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration-7000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration1362000000JPY
Income before income taxesPrior1YTDDuration3612000000JPY
Income before income taxesCurrentYTDDuration5001000000JPY
Depreciation and amortization ope cfPrior1YTDDuration875000000JPY
Depreciation and amortization ope cfCurrentYTDDuration1649000000JPY
Amortization of goodwill ope cfPrior1YTDDuration1675000000JPY
Amortization of goodwill ope cfCurrentYTDDuration2195000000JPY
Increase decrease in provision for directors retirement benefits ope cfPrior1YTDDuration-4000000JPY
Increase decrease in provision for directors retirement benefits ope cfCurrentYTDDuration-8000000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration-2000000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration2000000JPY
Increase decrease in provision for bonuses ope cfPrior1YTDDuration124000000JPY
Increase decrease in provision for bonuses ope cfCurrentYTDDuration44000000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration0JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-2000000JPY
Increase decrease in refund liabilities ope cfPrior1YTDDuration-JPY
Increase decrease in refund liabilities ope cfCurrentYTDDuration-1182000000JPY
Loss gain on sales and retirement of noncurrent assets ope cfPrior1YTDDuration23000000JPY
Loss gain on sales and retirement of noncurrent assets ope cfCurrentYTDDuration40000000JPY
Loss gain on step acquisitions ope cfPrior1YTDDuration-JPY
Loss gain on step acquisitions ope cfCurrentYTDDuration214000000JPY
Loss gain on sales of investment securities ope cfPrior1YTDDuration-JPY
Loss gain on sales of investment securities ope cfCurrentYTDDuration0JPY
Surrender value of insurance ope cfPrior1YTDDuration-1000000JPY
Surrender value of insurance ope cfCurrentYTDDuration-25000000JPY
Interest and dividends income ope cfPrior1YTDDuration-3000000JPY
Interest and dividends income ope cfCurrentYTDDuration-5000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass